Last reviewed · How we verify
ULO
ULO is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption.
ULO is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption. Used for Chronic gout management and serum uric acid lowering.
At a glance
| Generic name | ULO |
|---|---|
| Also known as | MK-8507, Ulonivirine., ulonivirine |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Uricosuric agent; URAT1 inhibitor |
| Target | URAT1 (urate transporter 1) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology; Gout |
| Phase | FDA-approved |
Mechanism of action
ULO works by blocking the urate transporter URAT1 in the proximal tubule of the kidney, preventing reabsorption of filtered uric acid and promoting its elimination in urine. This mechanism lowers serum uric acid levels without inhibiting xanthine oxidase, making it suitable for patients who cannot tolerate or have contraindications to xanthine oxidase inhibitors.
Approved indications
- Chronic gout management and serum uric acid lowering
Common side effects
- Headache
- Nausea
- Gout flare
- Renal-related adverse events
Key clinical trials
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012) (PHASE1)
- A Study of [14C]Ulonivirine ([14C]MK-8507) in Healthy Adults (MK-8507-006) (PHASE1)
- A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ULO CI brief — competitive landscape report
- ULO updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI